These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9301478)

  • 21. VEGF Trap(R1R2) suppresses experimental corneal angiogenesis.
    Oliveira HB; Sakimoto T; Javier JA; Azar DT; Wiegand SJ; Jain S; Chang JH
    Eur J Ophthalmol; 2010; 20(1):48-54. PubMed ID: 19882518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
    Bauer AJ; Terrell R; Doniparthi NK; Patel A; Tuttle RM; Saji M; Ringel MD; Francis GL
    Thyroid; 2002 Nov; 12(11):953-61. PubMed ID: 12490072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.
    Amano S; Rohan R; Kuroki M; Tolentino M; Adamis AP
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):18-22. PubMed ID: 9430540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules.
    Dueñas Z; Torner L; Corbacho AM; Ochoa A; Gutiérrez-Ospina G; López-Barrera F; Barrios FA; Berger P; Martínez de la Escalera G; Clapp C
    Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2498-505. PubMed ID: 10509642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
    Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
    Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide.
    Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y
    Biol Pharm Bull; 1999 Feb; 22(2):224-6. PubMed ID: 10077449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mouse cornea micropocket angiogenesis assay.
    Rogers MS; Birsner AE; D'Amato RJ
    Nat Protoc; 2007; 2(10):2545-50. PubMed ID: 17947997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo.
    Klauber N; Browne F; Anand-Apte B; D'Amato RJ
    Circulation; 1996 Nov; 94(10):2566-71. PubMed ID: 8921802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory corneal neovascularization: etiopathogenesis.
    Clements JL; Dana R
    Semin Ophthalmol; 2011; 26(4-5):235-45. PubMed ID: 21958169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.
    Castro MR; Lutz D; Edelman JL
    Exp Eye Res; 2004 Aug; 79(2):275-85. PubMed ID: 15325574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
    Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SR; Ahern R; Smith IE; Gore ME
    Br J Cancer; 2000 Feb; 82(4):812-7. PubMed ID: 10732751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid ocular angiogenic control via naked DNA delivery to cornea.
    Stechschulte SU; Joussen AM; von Recum HA; Poulaki V; Moromizato Y; Yuan J; D'Amato RJ; Kuo C; Adamis AP
    Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):1975-9. PubMed ID: 11481260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
    Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G
    Ann Oncol; 2001 Jul; 12(7):987-90. PubMed ID: 11521807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis.
    Abbas A; Khan B; Feroze AH; Hyman GF
    J Pak Med Assoc; 2002 Oct; 52(10):476-82. PubMed ID: 12553678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A peek into the atomic details of thalidomide's clinical effects.
    Bhogaraju S; Dikic I
    Nat Struct Mol Biol; 2014 Sep; 21(9):739-40. PubMed ID: 25192261
    [No Abstract]   [Full Text] [Related]  

  • 39. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
    Rofstad EK; Halsør EF
    Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.